This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.
Male or female patients ≥ 18 years of age at the time of study enrollment.
Body mass index (BMI) ≥ 17 kg/m2.
Patients diagnosed with glioblastoma must have unequivocal evidence of recurrence, as determined by contrast-enhanced magnetic resonance imaging (CE-MRI), following prior radiotherapy and temozolomide chemotherapy.
Patients may have undergone surgery for recurrence. The patients should have completed surgery and adequately recovered prior to the time of study enrollment.
Patients who have radiographic evidence of multifocal enhancing tumors.
Patients who have undergone previous treatment with anti-angiogenic therapy, including Bevacizumab, or other VEGF inhibitors or VEGF-receptor signaling inhibitors.
Patients who have previously received Carmustine wafers implantation during re-operation.
Patients who have previously received or are currently undergoing tumor treating fields (TTF) treatment.
NaviFUS Corporation
Lead sponsor
NaviFUS US LLC
Collaborator